Table 4 Associations between HLA- A alleles and clinical manifestations of BD
From: Associations between the HLA-Apolymorphism and the clinical manifestations of Behcet's disease
HLA alleles | Group | Phenotypic frequency n(%) | OR (95% CI) | P | Pc |
|---|---|---|---|---|---|
All subjects | Â | ||||
A*02:07 | Patients with skin lesions (n = 180) | 25 (13.9) | Â | Â | Â |
| Â | vs. Patients without skin lesions (n = 43) | 2 (4.7) | 3.31 (0.75 to 14.54) | 0.095 | Â |
| Â | vs. Controls (n = 1,398) | 89 (6.4) | 2.37 (1.48 to 3.31) | <0.0005 | <0.012 |
| Â | Patients with arthritis (n = 125) | 17 (13.6) | Â | Â | Â |
| Â | vs. Patients without arthritis (n = 98) | 10 (10.2) | 1.39 (0.60 to 3.18) | 0.438 | Â |
| Â | vs. Controls (n = 1,398) | 89 (6.4) | 2.32 (1.33 to 4.03) | 0.002 | 0.048 |
A*26:01 | Patients with uveitis (n = 85) | 15 (17.7) | Â | Â | Â |
| Â | vs. Patients without uveitis (n = 138) | 11 (8.0) | 2.47 (1.08 to 5.68) | 0.029 | Â |
| Â | vs. Controls (n = 1,398) | 93 (6.7) | 3.01 (1.66 to 5.46) | <0.0005 | <0.012 |
A*30:04 | Patients with vascular lesions (n = 33) | 6 (18.2) | Â | Â | Â |
| Â | vs. Patients without vascular lesions (n = 190) | 6 (3.2) | 6.81 (2.05 to 22.66) | 0.003 | Â |
| Â | vs. Controls (n = 1,398) | 31 (2.2) | 9.80 (3.78 to 25.43) | <0.0005 | <0.012 |
| Â | Patients with genital ulcers (n = 159) | 10 (6.3) | Â | Â | Â |
| Â | vs. Patients without genital ulcers (n = 64) | 2 (3.1) | 2.08 (0.44 to 9.77) | 0.516 | Â |
| Â | vs. Controls (n = 1,398) | 31 (2.2) | 3.00 (1.42 to 6.16) | 0.006 | 0.14 |
| Â | Patients with positive pathergy test (n = 94) | 8 (8.5) | Â | Â | Â |
| Â | vs. Patients with negative pathergy test (n = 88) | 3 (3.4) | 2.19 (0.74 to 6.46) | 0.147 | Â |
| Â | vs. Controls (n = 1,398) | 31 (2.2) | 4.10 (1.83 to 9.20) | 0.002 | 0.048 |
HLA-B*51 non-carriers | Â | ||||
A*02:07 | Patients with skin lesions (n = 109) | 17 (15.6) | Â | Â | Â |
| Â | vs. Patients without skin lesions (n = 33) | 2 (6.1) | 2.86 (0.63 to 13.10) | 0.243 | Â |
| Â | vs. Controls (n = 1,116) | 80 (7.2) | 2.39 (1.36 to 4.21) | 0.002 | 0.048 |
| Â | Patients with arthritis (n = 83) | 14 (16.9) | Â | Â | Â |
| Â | vs. Patients without arthritis (n = 59) | 5 (8.5) | 2.19 (0.74 to 6.46) | 0.147 | Â |
| Â | vs. Controls (n = 1,116) | 80 (7.2) | 2.63 (1.42 to 4.87) | 0.002 | 0.048 |
A*26:01 | Patients with uveitis (n = 48) | 11 (22.9) | Â | Â | Â |
| Â | vs. Patients without uveitis (n = 94) | 8 (8.5) | 3.20 (1.19 to 8.59) | 0.017 | Â |
| Â | vs. Controls (n = 1,116) | 74 (6.6) | 4.19 (2.05 to 8.54) | <0.0005 | <0.012 |
A*30:04 | Patients with vascular lesions (n = 24) | 6 (25.0) | Â | Â | Â |
| Â | vs. Patients without vascular lesions (n = 118) | 5 (4.2) | 7.53 (2.08 to 27.28) | 0.003 | Â |
| Â | vs. Controls (n = 1,116) | 26 (2.3) | 13.97 (5.13 to 38.08) | <0.00005 | <0.0012 |
| Â | Patients with genital ulcers (n = 106) | 9 (8.5) | Â | Â | Â |
| Â | vs. Patients without genital ulcers (n = 36) | 2 (5.6) | 1.58 (0.32 to 7.67) | 0.730 | Â |
| Â | vs. Controls (n = 1,116) | 26 (2.3) | 3.89 (1.77 to 8.54) | 0.002 | 0.048 |
| Â | Patients with positive pathergy test (n = 57) | 7 (12.3) | Â | Â | Â |
| Â | vs. Patients with negative pathergy test (n = 58) | 3 (5.2) | 2.57 (0.63 to 10.47) | 0.203 | Â |
| Â | vs. Controls (n = 1,116) | 26 (2.3) | 5.87 (2.43 to 14.17) | 0.001 | 0.024 |